This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine th…

Advanced Prostate CancerMetastatic Prostate CancerMetastatic Prostate Neuroendocrine Carcinoma

~Estimated

~$10 – $6,250

Brigham and Women's HospitalNCT06062745

Phase 1

A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors

The purpose of this study is to determine: 1. The highest dose of the trial intervention that targets neuroendocrine tumors and is tolerated by patients. 2. T…

Neuroendocrine CarcinomaNeuroendocrine Tumors

~Estimated

~$10 – $7,500

Peter Hosein, MDNCT06889493

Phase 1

PARP-1 Targeting With the Novel Radiotracer [18F]FTT in Pancreatic Neuroendocrine Tumors

A pilot study to evaluate the expression of PARP-1 in patients with pancreatic neuroendocrine tumors will be conducted. This will be done via the use of a nove…

Neuroendocrine Carcinoma MetastaticPancreatic Tumors

~Estimated

~$10 – $6,250

Abramson Cancer Center at Penn MedicineNCT07114939

← PreviousPage 3 of 3Next →